TD has acquired Cowen Inc. Please bookmark TD Securities for further updates.

$264.5 Million

Nuvalent, Inc.

Follow-on Offering

Bookrunner, October 2022

Nuvalent, Inc.

Nuvalent, Inc. (“Nuvalent” or the “Company”) (NUVL) is a clinical stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. The Company leverages deep expertise in chemistry and structure-based drug design to develop innovative small molecules that are designed with the aim to overcome the limitations of existing therapies for “clinically proven” kinase targets, or those kinase targets for which others have developed established, approved therapies that are used in the clinical setting. By addressing the limitations of existing therapies, Nuvalent believes their programs have the potential to drive deeper, more durable responses with minimal adverse events. The Company believes these potential benefits will support opportunities for clinical utility earlier in the treatment paradigm.